# US 2003/0204074 A1 · Streptococcus pneumoniae 37-kDa surface adhesin a protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0204074 A1
- Document ID: US20030204074A1
- Status: Published application
- Kind: A1
- Application number: 10/455,109
- Filed: 2003-06-04
- Published: 2003-10-30
- Earliest claimed: 1991-09-17
- Assignees: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, c/o Centers for Disease Control and Prevention
- Inventors: Jacquelyn Sampson; Harold Russell; Jean A, Tharpe; Edwin W. Ades; George M. Carlone
- Web page: https://patentgrep.com/patent/US20030204074A1

## CPC

- C07K 14/3156: {from Streptococcus pneumoniae (Pneumococcus) (Streptokinase C07K14/3153)}
- A61P 31/04: Antibacterial agents
- C07K 16/1275: Streptococcus (G)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Further provided is a method of detecting the presence of Streptococcus pneumoniae in a sample comprising the steps of contacting a sample suspected of containing Streptococcus pneumoniae with nucleic acid primers capable of hybridizing to a nucleic acid comprising a portion of the nucleic acid encoding the 37-kDa protein, amplifying the nucleic acid and detecting the presence of an amplification product, the presence of the amplification product indicating the presence of Streptococcus pneumoniae in the sample. Further provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens, methods of preventing and treating Streptococcus pneumoniae infection in a subject.

## Claims

### Claim 1

An isolated nucleic acid encoding the 37-kDa protein of Streptococcus pneumoniae as set forth in the Sequence Listing as SEQ ID NO:2.

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, wherein the nucleic acid is the nucleic acid set forth in the Sequence Listing as SEQ ID NO:1.

### Claim 3

An isolated nucleic acid comprising a unique fragment of at least 10 nucleotides of the nucleic acid set forth in the Sequence Listing as SEQ ID NO: 1.

### Claim 4

An isolated nucleic acid comprising the nucleic acid as set forth in the Sequence Listing as SEQ ID NO:3.

### Claim 5

An isolated nucleic acid comprising the nucleic acid as set forth in the Sequence Listing as SEQ ID NO:4.

### Claim 6 (depends on 1)

The isolated nucleic acid of claim 1 in a vector suitable for expressing the nucleic acid.

### Claim 7 (depends on 6)

The vector of claim 6 in a host suitable for expressing the nucleic acid.

### Claim 8 (depends on 3)

The isolated nucleic acid of claim 3 in a vector suitable for expressing the nucleic acid.

### Claim 9 (depends on 8)

The vector of claim 8 in a host suitable for expressing the nucleic acid.

### Claim 10 (depends on 2)

A purified polypeptide encoded by the nucleic acid of claim 2.

### Claim 11 (depends on 3)

A purified polypeptide encoded by the nucleic acid of claim 3.

### Claim 12 (depends on 10)

A purified antibody which selectively binds with the polypeptide of claim 10.

### Claim 13 (depends on 11)

A purified antibody which selectively binds with the polypeptide of claim 11.

### Claim 14 (depends on 10)

A vaccine comprising an immunogenic polypeptide of claim 10 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 11)

A vaccine comprising an immunogenic polypeptide of claim 11 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 2)

A method of detecting the presence of the Streptococcus pneumoniae in a sample, comprising the steps of:
a) contacting a sample suspected of containing Streptococcus pneumoniae with nucleic acid primers capable of hybridizing to a nucleic acid comprising a unique portion of the nucleic acid of claim 2;
b) amplifying the nucleic acid comprising a portion of the nucleic acid of claim 2;
c) detecting the presence of an amplification product, the presence of the amplification product indicating the presence of Streptococcus pneumoniae in the sample.

### Claim 17 (depends on 10)

A method of detecting the presence of Streptococcus pneumoniae in a subject, comprising the steps of:
a) contacting an antibody-containing sample from the subject with the polypeptide of claim 10; and
b) detecting the binding of the antibody with the polypeptide, the binding indicating the presence of Streptococcus pneumoniae in the subject.

### Claim 18 (depends on 11)

A method of detecting the presence of Streptococcus pneumoniae in a subject, comprising the steps of:
a) contacting an antibody-containing sample from the subject with the polypeptide of claim 11; and
b) detecting the binding of the antibody with the polypeptide, the binding indicating the presence of Streptococcus pneumoniae in the subject.

### Claim 19 (depends on 12)

A method of detecting the presence of Streptococcus pneumoniae in a subject, comprising the steps of:
a) contacting a sample from the subject with the antibody of claim 12; and
b) detecting the binding of the antibody with an antigen, the binding indicating the presence of Streptococcus pneumoniae in the subject.

### Claim 20 (depends on 13)

A method of detecting the presence of Streptococcus pneumoniae in a subject, comprising the steps of:
a) contacting a sample from the subject with the antibody of claim 13; and
b) detecting the binding of the antibody with an antigen, the binding indicating the presence of Streptococcus pneumoniae in the subject.

### Claim 21 (depends on 14)

A method of preventing Streptococcus pneumoniae infection in a subject, comprising administering to the subject a prophylactically effective amount of the vaccine of claim 14 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 15)

A method of preventing Streptococcus pneumoniae infection in a subject, comprising administering to the subject a prophylactically effective amount of the vaccine of claim 15 and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 10)

A method of preventing Streptococcus pneumoniae infection in a subject, comprising administering to the subject a prophylactically effective amount of an anti-idiotype antibody to the polypeptide of claim 10 and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 11)

A method of preventing Streptococcus pneumoniae infection in a subject, comprising administering to the subject a prophylactically effective amount of an anti-idiotype antibody to the polypeptide of claim 11 and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 12)

A method of treating a Streptococcus pneumoniae infection in a subject, comprising administering to the subject a therapeutically effective amount of the antibody of claim 12 and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 13)

A method of treating a Streptococcus pneumoniae infection in a subject, comprising administering to the subject a therapeutically effective amount of the antibody of claim 13 and a pharmaceutically acceptable carrier.
